Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| EyePoint, Inc.EYPT · Entity 5702 | Director | January 11, 2024 | January 16, 2024 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
EyePoint, Inc.
Report date January 11, 2024 · Filed January 16, 2024
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common Stock, $0.001 par valueSEC Table I · non-derivative | IndirectOcumension Therapeutics | 100,221 |
Reported balance
After 2024-01-11 transaction · row 1
Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source rowRow 1 · 2024-01-11 · Sale · Disposed 1,910,500 · Balance 100,221 F1: The shares are held by Ocumension Therapeutics. The reporting person is Chief Executive Officer and a Director of Ocumension Therapeutics. The reporting person disclaims beneficial ownership of the reported securities except to the extent of his pecuniary interest therein. |
Filing footnotes · ownership attribution and instrument terms
F1: The shares are held by Ocumension Therapeutics. The reporting person is Chief Executive Officer and a Director of Ocumension Therapeutics. The reporting person disclaims beneficial ownership of the reported securities except to the extent of his pecuniary interest therein.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| January 11, 2024 Filed Jan 16, 2024 23:01 UTC | EyePoint, Inc. EYPT · Entity 5702 | SaleCommon Stock, $0.001 par value | 1,910,500 | $19.45 | $37,159,225.00 |
DisclosureSEC source: 0001562180-24-000466 · primarydocument.xml · nonDerivative · entry 1 Liu Ye · CIK 0001840407 · Director 10b5-1 filing: No plan indicated Ownership: Indirect · Ocumension Therapeutics Disclosed balance after: 100,221 F1 · ownership.nature: The shares are held by Ocumension Therapeutics. The reporting person is Chief Executive Officer and a Director of Ocumension Therapeutics. The reporting person disclaims beneficial ownership of the reported securities except to the extent of his pecuniary interest therein. Read SEC document |
| December 06, 2023 Filed Dec 8, 2023 02:03 UTC | EyePoint, Inc. EYPT · Entity 5702 | SaleCommon Stock, $0.001 par value | 266,242 | $18.41 | $4,901,515.22 |
DisclosureSEC source: 0001562180-23-008222 · primarydocument.xml · nonDerivative · entry 2 Liu Ye · CIK 0001840407 · Director 10b5-1 filing: No plan indicated Ownership: Indirect · Ocumension Therapeutics Disclosed balance after: 2,010,721 F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $18.17 to $18.49. The reporting person undertakes to provide EyePoint Pharmaceuticals Inc., any security holder of EyePoint Pharmaceuticals Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F2 · ownership.nature: The shares are held by Ocumension Therapeutics. The reporting person is Chief Executive Officer and a Director of Ocumension Therapeutics. The reporting person disclaims beneficial ownership of the reported securities except to the extent of his pecuniary interest therein. Read SEC document |
| December 05, 2023 Filed Dec 8, 2023 02:03 UTC | EyePoint, Inc. EYPT · Entity 5702 | SaleCommon Stock, $0.001 par value | 733,758 | $19.91 | $14,609,121.78 |
DisclosureSEC source: 0001562180-23-008222 · primarydocument.xml · nonDerivative · entry 1 Liu Ye · CIK 0001840407 · Director 10b5-1 filing: No plan indicated Ownership: Indirect · Ocumension Therapeutics Disclosed balance after: 2,276,963 F1 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $18.80 to $20.38. The reporting person undertakes to provide EyePoint Pharmaceuticals Inc., any security holder of EyePoint Pharmaceuticals Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F2 · ownership.nature: The shares are held by Ocumension Therapeutics. The reporting person is Chief Executive Officer and a Director of Ocumension Therapeutics. The reporting person disclaims beneficial ownership of the reported securities except to the extent of his pecuniary interest therein. Read SEC document |
| May 30, 2023 Filed May 31, 2023 21:22 UTC | EyePoint, Inc. EYPT · Entity 5702 | SaleCommon Stock, $0.001 par value | 1 | $6.00 | $6.00 |
DisclosureSEC source: 0001562180-23-004632 · primarydocument.xml · nonDerivative · entry 1 Liu Ye · CIK 0001840407 · Director 10b5-1 filing: No plan indicated Ownership: Indirect · Ocumension Therapeutics Disclosed balance after: 3,010,721 F1 · kind: Sale of one share to test new broker F2 · ownership.nature: The shares are held by Ocumension Therapeutics. The reporting person is Chief Executive Officer and a Director of Ocumension Therapeutics. The reporting person disclaims beneficial ownership of the reported securities except to the extent of his pecuniary interest therein. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.